Rhythm

Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA®▼ Undergoing Diagnostic or Therapeutic Procedures

MUNICH, March 19, 2019 /PRNewswire/ — In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA®▼ (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural management and outcomes It is […]

New Data for Abbott’s HeartMate 3™ Highlights Unparalleled Performance of Industry’s Leading Heart Pump

NEW ORLEANS, March 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world’s largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint […]

Impella RP Post-Approval Study Data Presented at ACC 2019

March 18, 2019 07:00 AM Eastern Daylight Time NEW ORLEANS, La.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies and the maker of the Impella RP heart pump, announces that survival data from the 18 month post-approval study of 42 Impella RP patients was presented at the American College of Cardiology’s […]

FDA Approves Industry’s Smallest, Slimmest 3T Tachycardia Devices from BIOTRONIK

LAKE OSWEGO, Ore., March 14, 2019 /PRNewswire/ — BIOTRONIK today announced FDA approval of the Acticor and Rivacor high-voltage cardiac rhythm management (CRM) device families for treatment of patients with cardiac arrhythmias. The six new tachycardia solutions include Rivacor VR-T, Rivacor DR-T, Rivacor HF-T QP, Acticor DX, Acticor CRT-DX Bipolar and Acticor […]

Study Finds Advantages of Full-disclosure Mobile Telemetry Monitoring over Patch and Holter Methods to Diagnose Patients with Bradyarrhythmia

NEW ORLEANS, March 14, 2019 /PRNewswire/ — Medi-Lynx Cardiac Monitoring, LLC, a leading provider of cardiac monitoring solutions, today announced results from a large retrospective analysis which demonstrated that cardiac monitoring with full-disclosure mobile cardiac telemetry (PocketECG) for up to 30 days significantly increased diagnostic yield for patients with bradyarrhythmia over Patch and […]

LindaCare to Debut ProPulse™ Cardiac Remote Monitoring Services at ACC in New Orleans

LEUVEN, Belgium and HARTFORD, Conn., March 14, 2019 /PRNewswire/ — LindaCare, a digital health company specializing in remote patient monitoring solutions for chronic disease management, today announced the company will offer ProPulse™, a new remote monitoring service for patients with cardiac implantable devices, adding to its online device management software solution. Dr. Robert Lerman, LindaCare’s Chief […]

Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in Europe. Patients with AF are five times more likely to suffer a stroke than someone with a normal heart […]

Sotera Wireless to Showcase Newest ViSi Mobile® 1.5G Capability at AONE Conference in April

SAN DIEGO–(BUSINESS WIRE)–Sotera Wireless, maker of the ViSi Mobile® Surveillance Monitoring System and a pioneer in continuous vital signs monitoring, announced it will be exhibiting at the American Organization of Nurse Executives (AONE), the leading voice of nursing leadership in health care. The 4-day event brings nurse leaders together to […]

Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation

JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin […]

Boston Scientific Announces Scheduled Data at EHRA 2019 Congress

MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March 17-19. Two late-breaking clinical trials will be presented, including: Outcomes from AF-FICIENT I, a prospective, multicenter, single arm […]